Clinical trial
Effects of Remodulin in Patients With Critical Limb Ischemia Following a Vein…
NCT00067041 · United Therapeutics, Industry · Terminated
Key facts
| NCT number | NCT00067041 |
|---|---|
| Title | Effects of Remodulin in Patients With Critical Limb Ischemia Following a Vein Bypass Graft |
| Official title | A Randomized Placebo-Controlled, 12-Week Multicenter Study of the Safety and Efficacy of Remodulin in Patients With Critical Limb Ischemia Following an Autogenous Vein Infrainguinal Bypass Graft |
| Lead sponsor | United Therapeutics, Industry |
| Status | Terminated |
| Phase | Phase 2/Phase 3 |
| Study type | Interventional |
| Conditions | Peripheral Vascular Disease |
| Intervention type | Drug |
| Interventions | Remodulin (treprostinil sodium) Injection |
| Enrollment | 30 |
| Start date | Mar 1, 2003 |
| Primary completion | Dec 1, 2003 |
| Completion | Dec 1, 2003 |
| First posted | Aug 13, 2003 |
| Last update posted | Mar 7, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: